GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Sinco Pharmaceutical Holdings Ltd (HKSE:06833) » Definitions » Net Change in Cash

Sinco Pharmaceutical Holdings (HKSE:06833) Net Change in Cash : HK$119 Mil (TTM As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Sinco Pharmaceutical Holdings Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Sinco Pharmaceutical Holdings's Net Change in Cash for the six months ended in Dec. 2023 was HK$-91 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2023 was HK$119 Mil.

Sinco Pharmaceutical Holdings Net Change in Cash Historical Data

The historical data trend for Sinco Pharmaceutical Holdings's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sinco Pharmaceutical Holdings Net Change in Cash Chart

Sinco Pharmaceutical Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Change in Cash
Get a 7-Day Free Trial Premium Member Only Premium Member Only 160.70 -96.01 223.20 3.45 118.98

Sinco Pharmaceutical Holdings Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 72.31 153.15 -142.45 209.65 -90.67

Sinco Pharmaceutical Holdings Net Change in Cash Calculation

Sinco Pharmaceutical Holdings's Net Change in Cash for the fiscal year that ended in Dec. 2023 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=386.87+-69.593+-207.522+9.224
=119

Sinco Pharmaceutical Holdings's Net Change in Cash for the quarter that ended in Dec. 2023

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-78.845+-17.499+-1.352+7.022
=-91

Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$119 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sinco Pharmaceutical Holdings Net Change in Cash Related Terms

Thank you for viewing the detailed overview of Sinco Pharmaceutical Holdings's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Sinco Pharmaceutical Holdings (HKSE:06833) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Sinco Pharmaceutical Holdings Ltd (HKSE:06833) » Definitions » Net Change in Cash
Comparable Companies
HKSE:00673 HKSE:00718 HKSE:08372 HKSE:00401 HKSE:02289 HKSE:01931 MCK COR CAH HSIC SHSE:601607 HKSE:01099 MIL:AMP NZSE:EBO XSWX:GALE TSE:7459 TSE:2784 PDCO SHSE:600739 TSE:9987
Traded in Other Exchanges
N/A
Address
No. 1700, North Section of Tianfu Avenue, E5-1805, Global Centre, High-Tech Zone, Chengdu, Sichuan Province, Chengdu, CHN
Website
https://www.sinco-pharm.com
Sinco Pharmaceutical Holdings Ltd is an investment holding company engaged in the provision of comprehensive marketing, promotion, and channel management service for imported pharmaceutical products and medical devices in China. The company has three operating segments; the sale of imported pharmaceutical products segment, the research and manufacturing of aesthetic medicine segment, and the medical beauty services segment. Its product offering includes Human albumin solutions and Antibiotics like Axetine and Medocef.
Executives
Huang Zhijian 2305 Beneficiary of a trust
Fullwealth Holdings Limited 2201 Interest of corporation controlled by you
Risun Investments Limited 2101 Beneficial owner
Wickhams Cay Trust Company Limited 2301 Trustee
Huang Xiangbin 2307 Founder of a discretionary trust who can infl

Sinco Pharmaceutical Holdings (HKSE:06833) Headlines

No Headlines